Browse the corpus

OR Vitamin K antagonists for 4-6 weeks with a target INR of 2.0-3.0, with initial UFH or LMWH therapy overlap until the INR is 2.0 or more for 2 days Surveillance Δ LMWH: low molecular weight heparin; SC: subcutaneously; UFH: unfractionated heparin; aPTT: activated partial thromboplastin time; INR: international normalized ratio. * Although at extremes of body weight, modification of dose may be required. • May target an anti-Xa level in the therapeutic range of 0.6-1.0 units/mL for twice daily regimen; slightly higher doses may be needed for a once-daily regimen. Δ Clinical vigilance and appropriate objective investigation of women with symptoms suspicious of deep vein thrombosis or pulmonary embolism may be needed. Reproduced with permission from: ACOG Practice Bulletin #123. Thromboembolism in pregnancy. Obstet Gynecol 2011; 118:718. Copyright © 2011 Lippincott Williams & Wilkins.